Erratum: Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations (European Journal of Pediatrics DOI: 10.1007/s00431-011-1654-8);Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations

European Journal of Pediatrics

Volumn 171, Issue 5, 2012, Pages 833-841

  Paes, B ^a   Mitchell, I ^b   Li, A ^c   Lanctot K ^c  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Palivizumab; Premature; Respiratory syncytial virus; Special populations

Indexed keywords

PALIVIZUMAB;

ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DATA BASE; DISEASE REGISTRY; DOWN SYNDROME; DRUG UTILIZATION; FEMALE; GENERAL ASPECTS OF DISEASE; GESTATIONAL AGE; HAZARD RATIO; HIGH RISK INFANT; HOSPITALIZATION; HUMAN; INFANT; INFORMATION PROCESSING; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PREMATURITY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; STANDARD; UPPER RESPIRATORY TRACT INFECTION;

EID: 84860306234     PISSN: 03406199     EISSN: 14321076     Source Type: Journal    
DOI: 10.1007/s00431-012-1762-0     Document Type: Erratum

References (48)

1. Abman SH, Ogle JW, Butler-Simon N, Rumack CM, Accurso FJ (1988) Role of respiratory syncytial virus in early hospitalisations for respiratory distress of young infants with cystic fibrosis. J Pediatr 113:826-830
2. American Academy of Pediatrics (2009) From theAmerican Academy of Pediatrics: Policy statements - modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 124:1694-1701
3. Arnold SR, Wang EE, Law BJ, Boucher FD, Stephens D, Robinson JL, Dobson S, Langley JM, McDonald J, MacDonald NE, Mitchell I (1999) Variable morbidity of respiratory syncytial virus infection in patients with underlying lung disease: a review of the PICNIC RSV database. Pediatric Investigators Collaborative Network on Infections in Canada. Pediatr Infect Dis J 18:866-869 (Pubitemid 29487505)
4. Bloemers BL, Broers CJ, Bont L, Weijerman ME, Gemke RJ, van Furth AM (2010) Increased risk of respiratory tract infections in children with Down syndrome: the consequence of an altered immune system. Microbes Infect 12:799-808
5. Bloemers BL, van Furth AM, Weijerman ME, Gemke RJ, Broers CJ, Kimpen JL, Bont L (2010) High incidence of recurrent wheeze in children with down syndrome with and without previous respiratory syncytial virus lower respiratory tract infection. Pediatr Infect Dis J 29:39-42
6. Bloemers BL, van Furth AM, Weijerman ME, Gemke RJ, Broers CJ, van den Ende K, Kimpen JL, Strengers JL, Bont LJ (2007) Down syndrome: a novel risk factor for respiratory syncytial virus bronchiolitis - a prospective birth-cohort study. Pediatrics 120: e1076-e1081 (Pubitemid 47549555)
7. Boeckh M, Berrey MM, Bowden RA, Crawford SW, Balsley J, Corey L (2001) Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. J Infect Dis 184:350-354 (Pubitemid 32662183)
8. Boyce TG, Mellen BG, Mitchel EF Jr, Wright PF, Griffin MR (2000) Rates of hospitalisation for respiratory syncytial virus infection among children in medicaid. J Pediatr 137:865-870
9. Canadian Paediatric Society Infectious Diseases and Immunization Committee (1999) Palivizumab and respiratory syncytial virus immune globulin intravenous for the prophylaxis of respiratory syncytial virus infection in high risk infants. Paediatr Child Health 4:474-489
10. Canadian Paediatric Society Infectious Diseases and Immunization Committee, Langley JM (2003) Use of palivizumab in children without congenital heart disease. Paediatr Child Health 8:631-636
11. Canadian Paediatric Society Infectious Diseases and Immunization Committee, Samson L (2009) Prevention of respiratory syncytial virus infection. Paediatr Child Health 14:521-526
12. Carbonell-Estrany X, Lazaro y de Mercado P (2009) Health economics and RSV. Paediatr Respir Rev 10(Suppl 1):12-13
13. Cohen AH, Bomar R, Cohen LE, Lesnick B, Civgi V, Kirchner K, Graham L, Montgomery G, Scott P (2001) RSV prophylaxis using palivizumab in 86 high-risk children, outside AAP red book guidelines. American Pediatrics Scoeity/Society for Pediatric Research Annual Meeting, Baltimore, pp E-PAS2001:2656
14. Cohen AH, Boron ML, Dingivan C (2005) A phase IV study of the safety of synagis (palivizumab) for prophylaxis of respiratory syncytial virus disease in children with cystic fibrosis. International Conference of the American Thoracic Society, San Diego, Abstract A53
15. Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH Jr, Connor EM, Sondheimer HM (2003) Palivizumab prophylaxis reduces hospitalisation due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 143:532-540 (Pubitemid 37352516)
16. Figueras Aloy J, Carbonell Estrany X (2010) Recommendations for the use of palivizumab in the prevention of respiratory syncytial virus infection in late preterm infants (32(1) to 35(0) weeks of gestation). An Pediatr (Barc) 73:98 e91-98 e94
17. Frogel M, Nerwen C, Cohen A, Vanveldhuisen P, Harrington M, Boron M (2008) Prevention of hospitalisation due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry. J Perinatol 28:511-517 (Pubitemid 351973995)
18. Frogel MP, Stewart DL, Hoopes M, Fernandes AW, Mahadevia PJ (2010) A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis. J Manag Care Pharm 16:46-58
19. Giebels K,Marcotte JE, Podoba J, Rousseau C, DenisMH, Fauvel V, Laberge S (2008) Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis. Pediatr Pulmonol 43:169-174 (Pubitemid 351273044)
20. Giusti R (2009) North American synagis prophylaxis survey. Pediatr Pulmonol 44:96-98
21. Hall CB (2001) Respiratory syncytial virus and parainfluenza virus. N Engl J Med 344:1917-1928 (Pubitemid 32553362)
22. Hall CB, Powell KR, MacDonald NE, Gala CL, Menegus ME, Suffin SC, Cohen HJ (1986) Respiratory syncytial viral infection in children with compromised immune function. N Engl J Med 315:77-81 (Pubitemid 16093208)
23. Hiatt PW, Grace SC, Kozinetz CA, Raboudi SH, Treece DG, Taber LH, Piedra PA (1999) Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis. Pediatrics 103:619-626 (Pubitemid 29274510)
24. IMpact-RSV Study Group (1998) Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalisation from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 102:531-537
25. Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, Dormitzer M, O'Grady J, Koenig S, Tamura JK, Woods R, Bansal G, Couchenour D, Tsao E, Hall WC, Young JF (1997) Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 176:1215-1224 (Pubitemid 27460986)
26. Lanctot KL, Masoud ST, Paes BA, Tarride JE, Chiu A, Hui C, Francis PL, Oh PI (2008) The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis. Curr Med Res Opin 24:3223-3237
27. Law BJ, Carbonell-Estrany X, Simoes EA (2002) An update on respiratory syncytial virus epidemiology: a developed country perspective. Respir Med 96(Suppl B):S1-S7 (Pubitemid 39665384)
28. Law BJ, Langley JM, Allen U, Paes B, Lee DS, Mitchell I, Sampalis J, Walti H, Robinson J, O'Brien K, Majaesic C, Caouette G, Frenette L, Le Saux N, Simmons B, Moisiuk S, Sankaran K, Ojah C, Singh AJ, Lebel MH, Bacheyie GS, Onyett H, Michaliszyn A, Manzi P, Parison D (2004) The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalisation for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J 23:806-814 (Pubitemid 40221021)
29. Ljungman P, Ward KN, Crooks BN, Parker A, Martino R, Shaw PJ, Brinch L, BruneM, De La Camara R, Dekker A, Pauksen K, Russell N, Schwarer AP, Cordonnier C (2001) Respiratory virus infections after stemcell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 28:479-484 (Pubitemid 33069626)
30. Manzoni P, Leonessa ML, Galletto P, Gallo E, Sala U, Gomirato G, Farina D (2009) Use of palivizumab in neonates who do not meet the American Academy of Pediatrics Guidelines for respiratory syncytial virus prophylaxis. Early Hum Dev 85:S93
31. McCormick J, Southern KW (2007) A survey of palivizumab for infants with cystic fibrosis in the UK. Arch Dis Child 92:87-88 (Pubitemid 46132944)
32. Michaels MG, Fonseca-AtenM, GreenM, Charsha-May D, Friedman B, Seikaly M, Sanchez PJ (2009) Respiratory syncytial virus prophylaxis: a survey of pediatric solid organ transplant centers. Pediatr Transplant 13:451-456
33. Mitchell I, Paes BA, Li A, Lanctot KL (2011) CARESS: the Canadian registry of palivizumab. Pediatr Infect Dis J 30:651-655
34. Mori M, Kawashima H, Nakamura H, Nakagawa M, Kusuda S, Saji T, Tsutsumi H, Yokota S, Itoh S (2010) Nationwide survey of severe respiratory syncytial virus infection in children who do not meet indications for palivizumab in Japan. J Infect Chemother 17:254-263
35. Paes B, Manzoni P (2011) Special populations: do we need evidence from randomized controlled trials to support the need for respiratory syncytial virus prophylaxis? Early Hum Dev 87(Suppl 1):S55-S58
36. Paes BA (2003) Current strategies in the prevention of respiratory syncytial virus disease. Paediatr Respir Rev 4:21-27 (Pubitemid 36367581)
37. Resch B, Manzoni P, Lanari M (2009) Severe respiratory syncytial virus (RSV) infection in infants with neuromuscular diseases and immune deficiency syndromes. Paediatr Respir Rev 10:148-153
38. Saez-Llorens X, Castano E, Null D, Steichen J, Sanchez PJ, Ramilo O, Top FH Jr, Connor E (1998) Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group. Pediatr Infect Dis J 17:787-791 (Pubitemid 28475545)
39. Sampalis JS, Langley J, Carbonell-Estrany X, Paes B, O'Brien K, Allen U, Mitchell I, Aloy JF, Pedraz C, Michaliszyn AF (2008) Development and validation of a risk scoring tool to predict respiratory syncytial virus hospitalisation in premature infants born at 33 through 35 completed weeks of gestation. Med Decis Making 28:471-480 (Pubitemid 351989998)
40. Simoes EA (2002) Immunoprophylaxis of respiratory syncytial virus: global experience. Respir Res 3(Suppl 1):S26-S33
41. Simoes EA, Carbonell-Estrany X, Fullarton JR, Liese JG, Figueras-Aloy J, Doering G, Guzman J (2008) A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33-35 weeks of gestational age, based on data from the Spanish FLIP Study. Respir Res 9:78
42. Speer ME, Fernandes CJ, Boron M, Groothuis JR (2008) Use of palivizumab for prevention of hospitalisation as a result of respiratory syncytial virus in infants with cystic fibrosis. Pediatr Infect Dis J 27:559-561
43. Statistics Canada (2009) Quarterly demographic estimates: July to September 2009 (Catalogue # 91-002-X)
44. Thorburn K (2009) Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus infection. Arch Dis Child 94:99-103
45. Van Ewijk BE, Wolfs TF, Aerts PC, Van Kessel KP, Fleer A, Kimpen JL, Van der Ent CK (2007) RSV mediates Pseudomonas aeruginosa binding to cystic fibrosis and normal epithelial cells. Pediatr Res 61:398-403 (Pubitemid 46569290)
46. Welliver RC Sr, Checchia PA, Bauman JH, Fernandes AW, Mahadevia PJ, Hall CB (2010) Fatality rates in published reports of RSV hospitalisations among high-risk and otherwise healthy children. Curr Med Res Opin 26:2175-2181
47. Wilkesmann A, Ammann RA, Schildgen O, Eis-Hubinger AM, Muller A, Seidenberg J, Stephan V, Rieger C, Herting E, Wygold T, Hornschuh F, Groothuis JR, Simon A (2007) Hospitalized children with respiratory syncytial virus infection and neuromuscular impairment face an increased risk of a complicated course. Pediatr Infect Dis J 26:485-491 (Pubitemid 46847308)
48. Young J (2002) Development of a potent respiratory syncytial virus-specific monoclonal antibody for the prevention of serious lower respiratory tract disease in infants. Respir Med 96(Suppl B): S31-S35 (Pubitemid 39665388)